beta-Lactamase Inhibitors
"beta-Lactamase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES.
| Descriptor ID |
D065093
|
| MeSH Number(s) |
D27.505.519.389.400 D27.505.954.122.085.516
|
| Concept/Terms |
beta-Lactamase Inhibitors- beta-Lactamase Inhibitors
- Inhibitors, beta-Lactamase
- beta Lactamase Inhibitors
- Inhibitors, beta Lactamase
- Lactamase Inhibitors, beta
- beta Lactamase Antagonists
- Antagonists, beta Lactamase
- Lactamase Antagonists, beta
|
Below are MeSH descriptors whose meaning is more general than "beta-Lactamase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "beta-Lactamase Inhibitors".
This graph shows the total number of publications written about "beta-Lactamase Inhibitors" by people in this website by year, and whether "beta-Lactamase Inhibitors" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 2 | 3 |
| 2001 | 3 | 1 | 4 |
| 2002 | 3 | 0 | 3 |
| 2003 | 3 | 3 | 6 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 5 | 5 |
| 2007 | 2 | 1 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 2 | 4 |
| 2010 | 2 | 1 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 2 | 3 |
| 2016 | 5 | 0 | 5 |
| 2017 | 3 | 1 | 4 |
| 2019 | 3 | 0 | 3 |
| 2020 | 4 | 0 | 4 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
Below are the most recent publications written about "beta-Lactamase Inhibitors" by people in Profiles.
-
Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare. J Antimicrob Chemother. 2024 Nov 04; 79(11):2731-2741.
-
Identifying Artifacts from Large Library Docking. J Med Chem. 2024 Sep 26; 67(18):16796-16806.
-
Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation. Antimicrob Agents Chemother. 2024 Mar 06; 68(3):e0139923.
-
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review. Drugs. 2023 Jul; 83(11):967-983.
-
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults. Antimicrob Agents Chemother. 2022 12 20; 66(12):e0093622.
-
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older. Clin Pharmacol Ther. 2022 03; 111(3):635-645.
-
Mutation of the conserved Asp-Asp pair impairs the structure, function, and inhibition of CTX-M Class A β-lactamase. FEBS Lett. 2021 12; 595(24):2981-2994.
-
Probing the mechanisms of inhibition for various inhibitors of metallo-β-lactamases VIM-2 and NDM-1. J Inorg Biochem. 2020 09; 210:111123.
-
Structural analysis of avibactam-mediated activation of the bla and mec divergons in methicillin-resistant Staphylococcus aureus. J Biol Chem. 2020 08 07; 295(32):10870-10884.
-
Pyridine-2,6-Dithiocarboxylic Acid and Its Metal Complexes: New Inhibitors of New Delhi Metallo β-Lactamase-1. Mar Drugs. 2020 Jun 02; 18(6).